Anatara Lifesciences Ltd

ANR

AU000000ANR0

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 07:10:37 17/05/2024 BST			5-day change	1st Jan Change
0.039 ^AUD	-2.50%		-4.88%	+77.27%

05-01	Anatara Lifesciences Raises AU$1 Million via Shares Placement; Shares Decline 6%	MT
04-09	Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial	MT

Anatara Lifesciences Limited (ASX:ANR) Investor Presentation

September 06, 2021 at 12:59 am

Melbourne, Australia, Sep 6, 2021 - (ABN Newswire) - Anatara Lifesciences Limited (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in humans and animals, is pleased to release to investors a copy of the presentation that Chief Executive Officer, Mr. Steven Lydeamore, will present today to investors.

To view the Presentation, please visit:
https://abnnewswire.net/lnk/20846ZE6

About Anatara Lifesciences Limited:

Anatara Lifesciences Limited (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anatara is a life sciences company with expertise in developing products for animal and human health. Anatara is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders. For more information, please visit www.anataralifesciences.com.

Contact:

Steven Lydeamore
CEO, Anatara Lifesciences Ltd
+61 (0) 438 027 172
slydeamore@anatara.com

Eric Kuret
Market Eye
+61 (0) 417 311 335
eric.kuret@marketeye.com.au

Latest news about Anatara Lifesciences Ltd

Anatara Lifesciences Raises AU$1 Million via Shares Placement; Shares Decline 6%	05-01	MT
Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial	04-09	MT
Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Anatara Lifesciences Raised Nealy AU$960,000 Via Entitlement Offer	12-08	MT
Anatara Lifesciences Ltd Announces Board Changes	01/10/23	CI
Anatara Lifesciences to Proceed to Stage II of IBS Drug Trial	28/09/23	MT
Anatara Lifesciences Finalizes Patients for Irritable Bowel Syndrome Clinical Trial Stage One	31/08/23	MT
Anatara Lifesciences Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	24/08/23	CI
Anatara Lifesciences Receives R&D Tax Rebate; Shares Up 3%	14/08/23	MT
Anatara Lifesciences Ltd Announces Registered Office Change	20/04/23	CI
Anatara Lifesciences Provides Update on the Gastrointestinal Reprogramming(Garp) Trial for IBS	09/03/23	CI
Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2022	23/02/23	CI
Anatara Lifesciences Ltd Announces board Changes	06/12/22	CI
Anatara Lifesciences Raising Funds for Patient Trial, Future Project Acquisitions	21/10/22	MT
Anatara Lifesciences Receives More than $310,000 R&D Tax Rebate	05/10/22	MT
CSIRO Halts Psychological Functioning Trial for Dietary Supplement	03/10/22	MT
Anatara Lifesciences Limited Provides Updates on 3FDC Clinical Trial	02/10/22	CI
Anatara Lifesciences Limited Reports Earnings Results for the Full Year Ended June 30, 2022	29/08/22	CI
Anatara Lifesciences Modifies Protocol for Upccoming Gastrointestinal Disease Trial	11/08/22	MT
Anatara Lifesciences Limited Appoints John Michailidis as Chief Operations Officer	22/06/22	CI
Anatara Lifesciences Limited Announces to Provide an Update on the Progress of Clinical Trials in Irritable Bowel Syndrome and Psychological Functioning	22/06/22	CI
Anatara Lifesciences Expands Criteria for Irritable Bowel Trial	20/05/22	MT
Anatara Lifesciences Updates on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype	20/05/22	CI
Anatara Lifesciences CEO to Step Down	05/05/22	MT
Anatara Lifesciences Limited Announces Chief Executive Officer Changes	05/05/22	CI

Chart Anatara Lifesciences Ltd

Duration

Period

More charts

Company Profile

Anatara Lifesciences Ltd is an Australia-based life sciences company. The Company is engaged in developing evidence-based solutions for gastrointestinal diseases in humans and animals. Its products include Gastrointestinal ReProgramming (GaRP), Detach, BONIFF, and ANR-pf. Its GaRP Product is a microbiome-targeted multi-component complementary medicine, which is designed to address the primary underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Detach is a non-antibiotic approach to aid in the control of diarrheal disease known as scour, which is developed using bromelain. BONIFF is a revised formulation which is applied to dry feed for piglets after weaning, reducing labor input, and simplifying the entire process. ANR-pf is an enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method.

Sector

Pharmaceuticals

Calendar

26/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ANATARA LIFESCIENCES LTD	+77.27%	4.38M
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B